Stereotaxis reports first GenesisX U.S. purchase and catheter growth
Stereotaxis reported accelerating adoption across its robotic catheter, operating-room and robotic-system portfolio alongside $7.7 million of second-quarter revenue.
Evidence notes
- Quarterly revenue from the company's robotic catheters exceeded $1 million, up 270% sequentially.
- A U.S. hospital placed the first GenesisX purchase, with installation planned for autumn 2026.
- Multiple Synchrony digital operating-room systems were sold and installed after FDA clearance in April.
Company context
Stereotaxis develops robotic magnetic navigation systems for minimally invasive endovascular procedures, with Genesis as its core robotic platform.